Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the analysis of blazon II diabetes . Two pharmacological characteristics that sets linagliptin afar from added DPP-4 inhibitors is that it has a non-linear pharmacokinetic contour and is not primarily alone by the renal system.

Linagliptin is a aggressive and capricious dipeptidyl peptidase (DPP)-4 agitator inhibitor that slows the breakdown of insulinotropic hormone glucagon-like peptide (GLP)-1 for bigger glycemic ascendancy in diabetes patients. GLP and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that access the assembly and absolution of insulin from pancreatic beta beef and abatement the absolution of glucagon from pancreatic alpha cells. This after-effects in a all-embracing abatement in glucose assembly in the alarmist and access an of insulin in a glucose-dependent manner.

Linagliptin is acclimated for the administration of blazon 2 diabetes mellitus.